Genmab A/S
Close on Nov 20, 2026
Genmab A/S Direct Net Product Sales & Other Collaboration by Quarter
Direct Net Product Sales & Other Collaboration Counterparties ($M)
Genmab A/S Direct Net Product Sales & Other Collaboration: $27M in Q3 2026, up 107.7% from a year earlier. That is the highest of the 11 quarters on record here.
Where the Q3 2026 figure comes from
“|| Other** | 27 | 13 | 65 | 15”
Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
Combines Genmab's direct net product sales (EPKINLY U.S./Japan & Tivdak Japan/Europe) with Amgen TEPEZZA royalties and smaller collaborations.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Genmab A/S Direct Net Product Sales & Other Collaboration ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/partner-other
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?